Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPAR-γ Antagonists with Anti-adipogenic Effects

Yifeng Jin*, Younho Han*, Daulat Bikram Khadka, Chao Zhao, Kwang Youl Lee & Won-Jea Cho

Conformational change in helix 12 can alter ligand-induced PPAR-γ activity; based on this reason, isoquinolinoquinazolinones, structural homologs of berberine, were designed and synthesized as PPAR-γ antagonists. Computational docking and mutational study indicated that isoquinolinoquinazolinones form hydrogen bonds with the Cys285 and Arg288 residues of PPAR-γ. Furthermore, SPR results demonstrated strong binding affinity of isoquinolinoquinazolinones towards PPAR-γ. Additionally, biological assays showed that this new series of PPAR-γ antagonists more strongly inhibit adipocyte differentiation and PPAR-γ2-induced transcriptional activity than GW9662.

The incidence of metabolic syndromes, including diabetes and heart disease, is increasing worldwide, and this has led to extensive research into adipogenesis. A ligand-dependent nuclear receptor, peroxisome proliferator-activated receptor γ (PPAR-γ), is the key regulator of adipogenesis1. PPAR-γ is highly conserved across all species and expressed predominantly in adipose tissue, macrophages, colon epithelium, and in skeletal muscle. PPAR-γ regulates gene expression related to adipogenesis and glucose metabolism. The PPAR-γ isoforms (PPAR-γ1, PPAR-γ2, and PPAR-γ3) are functionally identical; however, a recent report indicates that PPAR-γ2 is the principal regulator of adipogenesis2. As a result, PPAR-γ2 is a potential therapeutic target for type 2 diabetes mellitus, dyslipidemia, atherosclerosis, obesity, and other metabolic diseases3,4.

PPAR-γ agonists have been used to treat metabolic diseases for decades. Rosiglitazone1, an example of a thiazolidinedione (TZD) PPAR-γ agonist, is an insulin-sensitizing agent (Fig. 1A). However, the limitations and side-effects of TZDs, such as edema, weight gain, and increased incidence of heart attack, discouraged further development and prevented clinical application of TZD-based PPAR-γ agonists5. Thus, the development of novel agents that modulate PPAR-γ is required.

It has been reported that inhibition of PPAR-γ activity can also improve insulin sensitivity6. Interestingly, the PPAR-γ antagonist, SR-202 2, shows antiobesity and antidiabetic effects, and lacks the adverse effects caused by PPAR-γ agonists (Fig. 1A)7. A well-known PPAR-γ antagonist, GW9662 3, was identified in a competition-binding assay against the human ligand-binding domain (region E/F) of PPAR-γ. GW9662 has high binding affinity, and shows potential inhibitory activity towards PPAR-γ8. Berberine 4, a tetracyclic isoquinoline alkaloid, has been reported to suppress adipocyte differentiation in 3T3-L1 cells by inhibiting PPAR-γ and increasing insulin sensitivity9. Thus, the promising results of PPAR-γ antagonists led us to discover a novel class of agents that could be used to treat PPAR-γ-related diseases.

Usually, nuclear receptors regulate gene transcription by binding to DNA in conjunction with a variety of cofactors10. The binding site of cofactors, the activation function-2 (AF-2) region, is altered by a conformational change in helix 12 (H12). H12 structure-function models of nuclear receptor ligand binding domains (LBDs) have shown that, at the molecular level, ligand-modulated agonism and antagonism depends on the conformation of H12. In the case of PPAR-γ, it has been shown that agonists can stabilize the ligand-binding pocket through interaction with H1211,12. The 3D structure of the complex that is formed between PPAR-γ and the agonist...
Rosiglitazone 1 contains a hydrogen bond between a nitrogen atom in rosiglitazone and the hydroxyl group of Tyr473, which lies in H12 (PDB: 2PRG)13. This interaction helps rosiglitazone stabilize conformational changes in PPARγ, particularly in the transcription cofactor-binding AF-2 region of H1214. In contrast, a PPARγ antagonist, GW9662 (in non-covalent complex with PPARγ, PDB: 3E00) does not have any interaction with H1215.

The LBD of nuclear receptors that contains the AF-2 region, is the primary site investigated for drug discovery. Our research group has succeeded in designing androgen receptor antagonists, nicotinamides, and demonstrated that the antagonist effect of these analogues is a result of their effect on the conformation of H12; agonists lock the conformation of H12 giving a closed conformation of ligand binding pocket (LBP), while antagonists give an open conformation of LBP16. On the basis of this principle, we investigated and synthesized isoquinolinoquinazolinones as a novel class of PPARγ antagonists. Compared with well-known PPARγ antagonists, such as GW9662, isoquinolinoquinazolinones which resemble berberine can be expected to possess more drug-like characteristics. Herein, we report a new series of PPARγ antagonists, which is much more potent than GW9662 according to biological evaluations.

**Drug Design**

We have previously reported the modification of protoberberines by altering the ring size or introducing a heteroatom into ring B17–21. In order to investigate a new series of PPARγ antagonists, we initially focused on 5-oxaprotoberberines, a class of berberine biososteres. The oxaprotoberberines affected adipogenesis; however, the activity was not better than berberine (Table 1, 10a–h). For an effective rational design strategy for PPARγ antagonists, molecular modeling was used to study the interaction between oxaprotoberberines and the GW9662 binding pocket of the PPARγ-GW9662-RXRα-retinoic acid-NCoA-2-DNA complex (PDB: 3E00)15.

Oxaprotoberberines, as shown in Fig. 1B, do not interact with H12, and the tetracyclic core is positioned in a hydrophobic region of the pocket. In addition, the oxygen atom in ring B is close to Cys285; this gave rise to an idea of exchanging the O atom with -NH, to generate isoquinolinoquinazolinones (Fig. 1C, D).

The binding mode between isoquinolinoquinazolinones and PPARγ indicates that the new amino group is located exactly where it was predicted, interacts through hydrogen-bonding to the Cys285 amino acid residue on helix 3 of PPARγ, and does not affect the conformation of H12 (Fig. 1C). These results provided an incentive to investigate the effects of isoquinolinoquinazolinones on PPARγ inhibition and adipocyte differentiation.
Results and Discussion

The isoquinolinoquinazolinones 8a-o were synthesized using a strategy that was similar to our previously reported synthesis method of oxaprotoberberine 20. The synthesis of isoquinolinoquinazolinones 8 involved a cycloaddition reaction between lithiated toluamides and 2-aminobenzonitriles (Scheme S1). The o-toluamides 5 were deprotonated using n-BuLi and reacted with the 2-aminobenzonitriles 6 to give the 3-arylisoquinolones 7. Finally, intramolecular cyclization was performed using diiodomethane and K2CO3 as base. Furthermore, 8o was reduced with lithium aluminium hydride to give the dihydro derivative 9 (Scheme S2).

The GW9662-mediated inhibition of PPARγ was confirmed using an Oil Red O staining assay to measure adipocyte differentiation8. To investigate whether the novel compounds could inhibit adipocyte differentiation, 3T3-L1 preadipocytes were incubated with differentiation medium (MDI; insulin, dexamethasone, and isobutyl methyl xanthine) in the presence of increasing concentrations of isoquinolinoquinazolinones. Adipogenesis was analyzed using Oil Red O staining after treatment with the compounds. Most of the compounds showed potential inhibitory activity towards adipocyte differentiation (Fig. 2A and Table 1).

A brief structure and activity relationship (SAR) study was performed in the context of adipocyte differentiation inhibition. The different substituents in ring D affect the inhibitory activity of 5-oxaprotoberberines 10. Compounds that contained a methyl group at both the C10 and C11 positions or a methoxy group at both the C11 and C12 positions (10c and 10d) were more active than those with a single methyl group at C11 or C12 (10a and 10b). Installation of a methylene dioxyl group across the C2 and C3 positions in ring A also increased the inhibitory activities (10e, 44.8% and 10f, 30.5%). In the case of isoquinolinoquinazolinones, introducing a single methyl group at C10 (8f and 8g) or a methyl group at both C10 and C11 (8h-j) decreased the activity. Introducing a chlorine substituent at C2 or C3 (8e, 8g, 8i, 8j) can increase the inhibitory activity. Among all the compounds tested, the isoquinolinoquinazoline compounds that had methoxy groups at both C10 and C11 and a chlorine substituent on ring A (8n and 8o) inhibited adipocyte differentiation with the greatest potency (71.5% and 82.4%, respectively). The mechanisms of action of these two compounds were further investigated.

Prior to testing the PPARγ antagonist potential of isoquinolinoquinazolinones, their cytotoxicity in 3T3-L1 cells (normal cells) was examined. At a concentration of 25 μM, compounds 8n and 8o exhibited little or no

| Compound No. | R1  | R2  | R3  | R4  | Y   | X   | Inhibitory activity (%) |
|--------------|-----|-----|-----|-----|-----|-----|-------------------------|
| Berberine    | —   | —   | —   | —   | —   | —   | 71.4                    |
| GW9662      | —   | —   | —   | —   | —   | —   | 51.4                    |
| 10a         | CH3 | H   | H   | H   | H   | C=O | O           | 23.6 |
| 10b         | H   | CH3 | H   | H   | H   | C=O | O           | 25.7 |
| 10c         | H   | CH3 | CH3 | H   | H   | C=O | O           | 60.4 |
| 10d         | OCH3| OCH3| H   | H   | H   | C=O | O           | 62.5 |
| 10e         | CH3 | H   | H   | OCH3| O   | C=O | O           | 44.8 |
| 10f         | H   | CH3 | H   | OCH3| O   | C=O | O           | 30.5 |
| 10g         | H   | H   | CH3 | OCH3| O   | C=O | O           | 40.9 |
| 10h         | H   | H   | CH3 | OCH3| O   | C=O | O           | 38.8 |
| 8a          | H   | H   | H   | H   | H   | C=O | NH          | 53.0 |
| 8b          | CH3 | H   | H   | H   | H   | C=O | NH          | 49.0 |
| 8c          | CH3 | H   | H   | H   | Cl  | C=O | NH          | 30.9 |
| 8d          | H   | CH3 | H   | H   | H   | C=O | NH          | 53.9 |
| 8e          | H   | CH3 | H   | Cl  | H   | C=O | NH          | 63.3 |
| 8f          | H   | H   | CH3 | H   | H   | C=O | NH          | 28.6 |
| 8g          | H   | H   | CH3 | H   | Cl  | C=O | NH          | 42.4 |
| 8h          | H   | CH3 | CH3 | H   | H   | C=O | NH          | 41.6 |
| 8i          | H   | CH3 | CH3 | H   | Cl  | C=O | NH          | 49.8 |
| 8j          | H   | CH3 | CH3 | Cl  | H   | C=O | NH          | 53.0 |
| 8k          | H   | OCH3| H   | H   | H   | C=O | NH          | 56.1 |
| 8l          | H   | OCH3| H   | Cl  | H   | C=O | NH          | 39.1 |
| 8m          | H   | OCH3| H   | H   | Cl  | C=O | NH          | 28.1 |
| 8n          | H   | OCH3| OCH3| H   | Cl  | C=O | NH          | 71.5 |
| 8o          | H   | OCH3| OCH3| H   | Cl  | C=O | NH          | 82.4 |
| 9           | H   | OCH3| OCH3| H   | CH3| NH     | 62.5         |

Table 1. Inhibitory activity of 5-oxaprotoberberines 10 and isoquinolinoquinazolinones 8 on adipocyte differentiation. aRelative absorbance data from Oil Red O staining assay at 25 μM.
cytotoxic effect (>70% cell viability; Fig. 2B). These two compounds were then tested for PPARγ inhibitory activity.

PPARγ alone or together with CCAAT-enhancer-binding protein α (C/EBPα) regulates many adipocyte genes that are involved in creating and maintaining the adipocyte phenotype. To further analyze the effect of isoquinolinoquinazolinones on adipogenesis, the expression of the adipocyte marker genes (C/EBPα and PPARγ) was analyzed. The differentiation of 3T3-L1 cells into adipocytes was induced by incubating in MDI induction medium for 2 days followed by incubation in differentiation medium for an additional 6 days. After MDI-induced adipocyte differentiation of 3T3-L1 cells, adipogenic transcriptional factors were analyzed. The transcriptional factors C/EBPα and PPARγ were inhibited by 8n and 8o in terms of both protein (Fig. 2C,D) and RNA (Fig. 2E,F).
levels. In addition, the mRNA expression of the genes downstream of PPARγ including adiponectin and fatty acid synthase markers (FAS) were strongly reduced by treatment with 8o. The results indicated that isoquinolinoquinazolinones may suppress adipogenesis by affecting the PPARγ pathway.

To analyze whether isoquinolinoquinazolinones inhibit the transactivation of PPARγ, 3T3-L1 cells were cotransfected with full-length PPARγ2 expression vector with a peroxisome proliferator response element (PPRE)-driven luciferase reporter gene (PPRE-Luc) that has been reported to respond to PPARγ agonist rosiglitazone. The transcriptional activity was determined in 3T3-L1 cells transiently co-transfected with PPRE-driven luciferase reporter gene (PPRE-Luc) and PPARγ2 expression vector. After 24 h of transfection, the cells were cultured with indicated combination for 12 h. Luciferase activity was measured after 36 h. Isoquinolinoquinazolinone can competitively inhibit PPARγ2-induced transcriptional activity in the presence of rosiglitazone. Data show mean ± SD of at least three experiments. **$P<0.01$, +++$P<0.001$ as compared to cells transfected with PPARγ alone. **$P<0.01$, +++$P<0.001$ as compared to cells transfected with PPARγ and treated with rosiglitazone.

A molecular modeling study was conducted to examine the hypothetical binding modes of PPARγ and isoquinolinoquinazolinones including 8o that exhibited potent inhibitory activities. The surflex-Dock program in Sybyl-X 2.1.1 was used to dock isoquinolinoquinazolinones into the ligand binding site of PPARγ following the removal of the ligand from the 3D crystal structure of PPARγ-GW9662-RXRα-retinoic acid-NCoA-2-DNA complex (PDB: 3E00). According to the docking model, isoquinolinoquinazolinone 8o occupied the hydrophobic region of PPARγ-LBP (Fig. 4). The amino group in ring B and methoxyl group in ring D formed hydrogen bonds with Cys285 and Arg288, respectively. Moreover, isoquinolinoquinazolinone 8o was located far away from H12. Furthermore, docking models showed that the isoquinolinoquinazolinones like 8l, which lacked significant inhibitory effect on adipocyte differentiation (39.1%), despite of subtle structural difference (absence of 10-OCH$_3$) than the potent counterpart like 8o (inhibitory effect on adipocyte differentiation: 82.9%) was basically due to unfavorable orientation of the compound in the LBP (Fig. S2).

A surface plasmon resonance (SPR) analysis demonstrated that 8o binds to PPARγ2-LBD (Fig. S1). A Reichert SR7500 (Reichert, Depew, NY) biosensor was used to measure the binding affinity of rosiglitazone, GW9662,
and 8o with PPARγ2-LBD. PPARγ2 protein was immobilized on the sensor chip, and the response (in resonance unit, RU) as a result of binding was continuously recorded and presented graphically as a function of time. The association rate (ka also known as on rate (kon)), dissociation rate (kd also known as off rate (koff)), and equilibrium dissociation constant (KD) were calculated using the Scrubber 2 program (Table 2). Rosiglitazone binds to PPARγ2 quickly (ka: 24 M$^{-1}$s$^{-1}$) and dissociates easily (kd: 0.0867 s$^{-1}$) (Fig. S1A). On the other hand, GW9662 binds slowly to PPARγ2 (ka: 15.09 M$^{-1}$s$^{-1}$) but hardly dissociates (kd: 0.000059 s$^{-1}$) from the protein confirming the irreversible covalent linkage of the ligand with PPARγ (Fig. S1B). Compound 8o binds and dissociates from PPARγ with intermediate rates (ka: 24 M$^{-1}$s$^{-1}$; kd: 146.25 s$^{-1}$) (Fig. S1C). The binding affinity of 8o to PPARγ is 4-folds more than rosiglitazone (KD: 146.25 μM (8o), 581.88 μM (rosiglitazone)) but is 37-folds less than GW9662 (KD: 3.91 μM). The SPR result correlates well with the competitive assay of 8o and rosiglitazone.

To investigate the contribution site on the PPARγ2 to the interaction with 8o, we generated mutant forms of the PPARγ2 (Fig. 5). In the docking results, 8o showed the interaction with Cys285 and Arg288. Thus, we tested Cys-to-Gly (Cys285), Arg-to-Gly (Arg288) substitution mutants of PPARγ2. Interestingly, the substitution of Cys285 to Gly abolished the inhibitory effect of both GW9662 and 8o on PPARγ2 activity. However, the

---

**Figure 4.** Molecular docking mode of 8o in PPARγ (PDB: 3E00).

**Figure 5.** Mutational study. Residues Cys285 and Arg288 of PPARγ are important for 8o function. The transcriptional activity was determined in 3T3-L1 cells transiently co-transfected with PPRE-driven luciferase reporter gene (PPRE-Luc) and PPARγ2 (WT) or (C285G, R288G) expression vector. After 24 h of transfection, the cells were cultured with 5 μM GW9662 and 5 μM 8o respectively for 12 h. Luciferase activity was measured after 36 h. Error bars mean ± SD of at least three experiments. *P < 0.05, **P < 0.01.

---

**Table 2. The kinetic constants of rosiglitazone, GW9662, and 8o binding to PPARγ2-LBD.** ka: association rate constant, kd: dissociation rate constant and KD: equilibrium dissociation constant.
substitution of Arg288 to Gly abolished the inhibitory effect of 8o not in GW9662. The results indicated 8o has interaction with both Cys285 and Arg288, which are in agreement with the docking study.

Conclusion

Based on the PPARγ antagonist behavior of berberine and the fact that the LBD of PPARγ contains a coactivator binding site, we designed a series of isoquinolinoquinazolinones. This novel class of PPARγ antagonists was synthesized in two steps and inhibited 3T3-L1 adipocyte differentiation by inhibiting transcription factor PPARγ. Compound 8o more effectively suppressed PPARγ transactivation than the existing PPARγ antagonist GW9662. The potent inhibitory effect of the isoquinolinoquinazolinones was well explained by their docking mode in the LBP of PPARγ. A molecular modeling study showed that, as expected, it was the presence of a quinazolinone-NH in ring B that enabled the isoquinolinoquinazolinones to have higher PPARγ inhibitory activities than GW9662. All of the biological assays, the SPR results and mutation study indicated that we have successfully designed and synthesized a new series of potent PPARγ antagonists. SAR data and docking models can provide helpful guidance in designing PPARγ antagonists. All of these findings suggest that isoquinolinoquinazolinones might exert multiple therapeutic effects and are potential treatments for obesity, type 2 diabetes, hyperlipidemia, and other metabolic syndromes.

Experimental Procedures

General Information and Instrumentation. Melting points were determined using the capillary method with a MEL-TEMP® capillary melting point apparatus and were uncorrected. IR spectra were obtained on a Shimadzu LCMS-2010 EV liquid chromatograph mass spectrometer using the electron spray ionization (ESI) method. Elemental analyses were performed using a Thermo Fischer Flash 2000 elemental analyzer and all measured values are within ±0.3% of the theoretical values. Column chromatography was performed with Merck silica gel 60 (70–230 mesh). TLC was performed using plates coated with silica gel 60 F254 (Merck). Chemical reagents were purchased from Sigma-Aldrich and Tokyo Chemical Industry Co., Ltd. and were used without further purification. Solvents were distilled prior to use; THF was distilled from sodium/benzophene. All reactions were conducted under a nitrogen atmosphere in oven-dried glassware with magnetic stirring. The specifications of HPLC analysis are as follows: column, ACE C18-HL, 250 × 2.1 mm, flow rate, 0.2 mL/min; wavelength, 254 nm; mobile phase, acetonitrile:water (9:1, v/v). The purity of compounds was established by integration of the areas of all peaks detected and is reported for each final compound. All compounds tested in the biological assay showed more than 95% purity.

Synthesis of isoquinolinoquinazolinones. 3-(2-Aminophenyl)isoquinolin-1(2H)-one (7a). A 100-mL oven-dried, three-necked flask was sealed with septa and evacuated/backfilled with nitrogen gas (N2) three times before the starting reaction. A solution of N,N-diethyl-2-methyl-benzamide 5a (13.1 g, 68.8 mmol) and 2-aminobenzonitrile 6a (8.12 g, 68.8 mmol) in dry THF (30 mL) was added drop wise to a solution of n- BuLi (2.5M solution in hexane; 82 mL) in dry THF (20 mL) at −60 °C, and the reaction mixture was stirred at −78 °C overnight. The reaction mixture was quenched with saturated NH4Cl solution (100 mL). The mixture was added to water (200 mL), extracted with CH2Cl2, and washed with water and brine. The organic phase was dried over sodium sulfate and concentrated in vacuo. The resulting oil was purified by column chromatography eluting with n-hexane:ethyl acetate (2:1) to afford compound 7a as a yellow solid (9.07 g, 56%). Mp: 236.5–238.1 °C. 1H NMR (300 MHz, DMSO-d6): δ = 8.18 (d, J = 6.6 Hz, 1H), 7.71–7.62 (m, 2H), 7.48–7.43 (m, 1H), 7.13–7.08 (m, 2H), 6.77–6.74 (m, 1H), 6.62 (td, J = 7.5, 1.2 Hz, 1H), 6.60 (s, 1H), 5.14 (bs, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 146.1, 139.2, 138.1, 132.2, 129.7, 129.6, 126.3, 124.9, 119.1, 115.9, 115.4, 104.5. MS (ESI) m/z = 237 (M + H)+. Anal. Calcd. for C15H12N2O2: C, 75.82; H, 4.78; N, 8.33. Found: C, 75.68; H, 4.72; N, 8.33.

3-(2-Amino-5-chlorophenyl)-6,7-dimethoxyisoquinolin-1(2H)-one (7n). A suspension of compound 5g 7a (800 mg, 3.18 mmol), and n- BuLi (2.5M solution in hexane, 4 mL) to afford compound 7a as a yellow solid (9.07 g, 56%). Mp: 236.5–238.1 °C. 1H NMR (300 MHz, DMSO-d6): δ = 8.18 (d, J = 6.6 Hz, 1H), 7.71–7.62 (m, 2H), 7.48–7.43 (m, 1H), 7.13–7.08 (m, 2H), 6.77–6.74 (m, 1H), 6.62 (td, J = 7.5, 1.2 Hz, 1H), 6.60 (s, 1H), 5.14 (bs, 2H). 13C NMR (125 MHz, DMSO-d6): δ = 146.1, 146.1, 139.2, 138.1, 132.2, 129.7, 129.6, 126.3, 124.9, 119.1, 115.9, 115.4, 104.5. MS (ESI) m/z = 237 (M + H)+. Anal. Calcd. for C15H12N2O2: C, 75.82; H, 4.78; N, 8.33. Found: C, 75.68; H, 4.79; N, 8.33.

3-(2-Aminophenyl)isoquinolin-1(2H)-one (7a). A solution of n-BuLi (2.5M solution in hexane, 4 mL) to afford compound 7a as a yellow solid (9.07 g, 56%). Mp: 236.5–238.1 °C. 1H NMR (300 MHz, DMSO-d6): δ = 8.18 (d, J = 6.6 Hz, 1H), 7.71–7.62 (m, 2H), 7.48–7.43 (m, 1H), 7.13–7.08 (m, 2H), 6.77–6.74 (m, 1H), 6.53 (s, 1H), 5.29 (bs, 2H), 3.88 (s, 3H), 3.87 (s, 3H). MS (ESI) m/z = 331 (M + H)+. Anal. Calcd. for C15H12N2O2: C, 75.82; H, 4.78; N, 8.33. Found: C, 75.68; H, 4.78; N, 8.33.
as a yellow solid (976 mg, 23%). Mp: 204.3–206.3 °C. IR (cm⁻¹): 3289, 1588. ¹H NMR (300 MHz, DMSO-d₆): δ: 8.20 (d, J = 7.8 Hz, 1H), 7.86 (d, J = 7.2 Hz, 1H), 7.71–7.69 (m, 2H), 7.48–7.41 (m, 2H), 7.28–7.22 (m, 1H), 7.17 (s, 1H), 6.92–6.89 (m, 1H), 6.83 (s, 1H), 6.83 (d, J = 7.8 Hz, 2H). MS (ESI) m/z = 249 (M + H)⁺. Anal. Calcd. for C₁₅H₁₂N₂O • 0.05 H₂O • 0.15 C₂H₅OH: C, 76.35; H, 5.04; N, 10.86. Found: C, 76.17; H, 4.86; N, 10.69. HPLC: tᵣ 2.00 min, purity 98.8%.

2-Chloro-10,11-dimethoxy-5H-isquinolino[2,3-c]quinazolin-8(6H)-one (8n). The procedure used to prepare compound 8a was carried out using compound 7n (200 mg, 0.60 mmol), K₂CO₃ (209 mg, 1.51 mmol), and diiodomethane (643 mg, 2.40 mmol) to afford compound 8a as a yellow solid (98 mg, 47%). Mp: 193.5–194.6 °C. IR (cm⁻¹): 3286, 1571. ¹H NMR (300 MHz, DMSO-d₆): δ: 8.33 (d, J = 3.0 Hz, 1H), 7.56 (s, 1H), 7.27–6.18 (m, 3H), 6.94 (bs, 1H), 6.90 (d, J = 9.0 Hz, 1H), 5.12 (d, J = 5.0 Hz, 1H), 3.90 (s, 3H), 8.37 (s, 3H). ¹C NMR (125 MHz, DMSO-d₆): δ: 158.8, 153.3, 148.8, 132.7, 130.2, 129.5, 123.5, 123.1, 119.2, 111.0, 117.5, 107.0, 106.9, 100.4, 55.6, 55.5. MS (ESI) m/z = 343 (M + H)⁺. Anal. Calcd. for C₁₅H₁₂ClN₂O • 0.1 H₂O • 0.05 C₂H₅OH • 0.8 CH₂Cl₂: C, 54.73; H, 4.16; N, 6.72. Found: C, 54.84; H, 4.05; N, 6.61. HPLC: tᵣ 1.99 min, purity 98.3%.

3-Chloro-10,11-dimethoxo-5H-isquinolino[2,3-c]quinazolin-8(6H)-one (8o). The procedure used to prepare compound 8a was carried out using compound 7o (100 mg, 0.37 mmol), K₂CO₃ (104 mg, 0.75 mmol), and diiodomethane (321 mg, 1.20 mmol) to afford compound 8o as a yellow solid (58 mg, 56%). Mp: 228.7–230.5 °C. IR (cm⁻¹): 3305, 1591. ¹H NMR (300 MHz, DMSO-d₆): δ: 7.80 (d, J = 5.0 Hz, 1H), 7.56 (s, 1H), 7.18 (s, 1H), 7.12 (s, 1H), 7.01 (s, 1H), 6.94–6.89 (m, 2H), 5.14 (d, J = 5.0 Hz, 2H), 3.90 (s, 3H), 3.87 (s, 3H). ¹C NMR (125 MHz, DMSO-d₆): δ: 158.8, 153.3, 148.8, 134.3, 134.3, 132.2, 130.5, 129.0, 116.5, 114.9, 107.0, 106.8, 99.8, 55.7, 55.5, 52.0. MS (ESI) m/z = 343 (M + H)⁺. Anal. Calcd. for C₁₅H₁₂ClN₂O • 0.1 C₂H₅OH • 0.1 CH₂Cl₂: C, 61.71; H, 4.48; N, 7.78. Found: C, 61.62; H, 4.31; N, 7.50. HPLC: tᵣ 1.93 min, purity 99.0%.

2-Chloro-6,8-dihydro-5H-isquinolino[2,3-c]quinazolin-9(8H)-one (9). Lithium hydromethy hydride (550 mg, 14.5 mmol) was added portion-wise to a stirred solution of 8o (400 mg, 1.61 mmol) in dry THF (20 mL) in a stream of nitrogen at 0 °C and stirring was continued for 1 h at room temperature. Thereafter, the reaction mixture was diluted with water and filtered. The filtrate was dried and concentrated in vacuo. The residue was purified by column chromatography eluting with n-hexane/water (5:1) to afford compound 9 as an ivory solid (110 mg, 30%). ¹H NMR (300 MHz, CDCl₃): δ: 8.66 (bs, 1H), 8.40 (d, J = 7.8 Hz, 1H), 7.70–7.65 (m, 1H), 7.57–7.47 (m, 2H), 7.38–7.32 (m, 1H), 7.27–7.24 (m, 1H), 6.82 (td, J = 7.5, 0.6 Hz, 1H), 6.75 (d, J = 8.1 Hz, 1H), 6.61 (s, 1H), 4.15 (s, 1H), 2.84 (d, J = 4.8 Hz, 3H). ¹C NMR (125 MHz, DMSO-d₆): δ: 162, 153, 149, 147, 136, 135, 133, 130, 117, 110, 107, 106, 56, 30. MS (ESI) m/z = 329 (M + H)⁺. HPLC: tᵣ 1.92 min, purity 99.9%.

Plasmids. For plasmids expressing PPARγ-2, full length PPARγ-2 (mouse, 1518 bp; NCBI Reference Sequence: NP_035276.2) was subcloned into CMV promoter-derived mammalian expression vector (pCS4). Plasmids for C285G, R288G mutant PPARγ-2 were generated by PCR-based site-directed mutagenesis and also subcloned into CMV promoter-derived mammalian expression vector (pCS4). Sequence of mutants was confirmed by Xenotech biology (Daejeon, Korea).

Cell culture and differentiation conditions. The mouse preadipocyte cell line 3T3-L1 was maintained at 37 °C in humidified air with 5% CO₂. 3T3-L1 cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Life Technologies) supplemented with 10% bovine serum (BS; Gibco Invitrogen, Carlsbad, California, USA) as growth medium. For adipocyte differentiation, cells were cultured for 2 days to full confluence in a 24-well plate and the growth medium was then replaced (day 0) with DMEM supplemented with 10% fetal bovine serum (FBS, Gibco Invitrogen, Carlsbad, California, USA), 5 μg/mL insulin (Sigma, St. Louis, Missouri, USA), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma), and 1 μM dexamethasone (Sigma). After 48 h, the differentiation medium was replaced (day 2) with DMEM + 10% FBS containing 5 μg/mL insulin, and the cells were allowed to accumulate lipid droplets until experimental use.

Luciferase reporter assays. 3T3-L1 cells were transfected for indicated combinations of expression plasmids along with a luciferase reporter plasmid (PPRE-Luc). PPRE-Luc contains the consensus PPAR responsive element (PPRE). pCMV-β-gal was co-transfected for normalization of transfection efficiency. 24 h after transfection, cells were treated with indicated compounds for 12 h. Luciferase activities were measured using a luciferase reporter assay kit (Promega, Madison, WI, USA). Experiments were performed in triplicate and repeated at least three times.

Oil Red O Staining. The accumulation of lipids signifying the formation of adipocytes was observed by staining the differentiated cells with Oil Red O. Following differentiation, cells were washed twice with phosphate-buffered saline (PBS), fixed with 10% formalin for 60 min. Oil Red O stock solution (0.5%) was prepared in isopropanol and filtered in cellulose nitrate filters. Cells were stained with Oil Red O diluted 6:4 in water for 1 h at room temperature. Excess Oil Red O dye was washed off twice with distilled water and then dried. The stained lipid droplets within cells were visualized using an optical microscope and photographed with a digital camera at 100× magnification.

RT-PCR analyses. Total cellular RNA was prepared using TRizol reagent (Life Technologies) according to the manufacturer’s instructions. Random-primed cDNAs were synthesized from 1 μg of total RNA using Super-Script III First-Strand Synthesis System (Life Technologies). The following conditions were used for PCR: initial denaturation at 94 °C for 1 min; 28–30 cycles of denaturation at 94 °C for 30 s, annealing at a temperature optimized for each primer pair for 30 s, extension at 72 °C for 30 s; final extension at 72 °C for 5 min. The following PCR primers were used: C/EBPα forward 5’-TGC TGG AGT TGA CCA GTG AC-3’ and reverse 5’-AAA CCA TCC TCT GGG TCT CC-3’; PPARγ forward 5’-ATC AGC TCT GTG GAC CTC TC-3’ and reverse 5’-ACC TGA
TGG CAT TGT GAG AC-3′; Adiponectin forward 5′-CAT CCC AGG ACA TCC TGG CCA CAA TG-3′ and reverse 5′-GCC CCT TCA GCT CCT GTT ATT CCA AC-3′; FAS forward 5′-GCT ATG CAG ATG GCT GTG TCT CCC AG-3′ and reverse 5′-GCA GGG CTG TTT ACA TCC CTC CCA GG-3′; GAPDH forward 5′-ACC ACA GTC CAT GCC ATC AC-3′ and reverse 5′-TCC ACC CTG TGG CTG TA-3′. RNA levels were quantified by image software, Multi Gauge, V3.0 (FUJI FILM).

Immunoblotting (IB). At the end of differentiation, 3T3-L1 cells were washed with PBS and lysed in a lysis buffer (1% NP-40, 25 mM HEPES (pH 7.5), 10% glycerol, 150 mM NaCl, 25 mM NaF, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and 250 μM phenylmethylsulfonyl fluoride). For immunoblotting (IB), Aliquots from the cell lysates containing 30 μg of protein were heated at 95°C for 5 min and were then separated using SDS-PAGE, and proteins were transferred to PVDF membrane. Blots were blocked for 30 min with Tris-buffered saline (50 mM Tris.HCl, pH 7.4, 150 mM NaCl)-0.05% Tween 20 (TBS-T) supplemented with 5% skim milk. The membranes were subsequently incubated with various primary antibodies; PPARγ (#MAB3872, 1:1000, Chemicon International), C/EBPα (#04-1104, 1:1000, Upstate Biotechnology), and α-tubulin (#B-5-1-2, 1:5000, Sigma-Aldrich). Horseradish peroxidase-labeled secondary antibodies were detected and visualized using chemiluminescent western blotting reagent (Millipore). Protein expression levels were quantified by image software, Multi Gauge, V3.0 (FUJI FILM).

Molecular docking. The docking study was performed in Sybyl-X 2.1.1 (winnt_os5x) using the Surflex Dock program. The structure of PPARγ-GW9662-RXRα-retinoic acid-NCoA-2 DNA complex was downloaded from the Protein Data Bank (PDB: 3E00). Structures of RXRα, retinoic acid, NCoA-2, and DNA were removed. The ligand (GW9662) was extracted. Hydrogens were added and minimization was performed using the MMFF94s force field with MMFF94 charges, by using a conjugate gradient method, distance dependent dielectric constant and converging to 0.01 kcal/mol Å. Protomol, an idealized representation of a ligand that makes every potential interaction with the binding site, was generated on the basis of ligand mode. Oxaprotoberberines and isoquinolinoquinazolines were constructed in Sybyl; energy was minimized with MMFF94s force field and MMFF94 charges and stored in a Sybyl database. The compounds in the Sybyl database were docked into the binding site by Surflex Dock on the basis of the protomol constructed earlier.

Expression and purification of mouse PPARγ2 ligand binding domain (PPARγ2-LBD) protein. The recombinant ligand-binding domains (LBDs) of mouse PPARγ2 (residues 230–505) were expressed as the recombinant ligand-binding domains (LBDs) of mouse PPARγ2 (residues 230–505) were expressed as

Surface Plasmon Resonance analysis. Analysis of the interaction between immobilized PPARγ2-LBD and rosiglitazone, GW9662 and 8o was performed using Reichert SR7500 Surface Plasmon Resonance dual channel instrument (Reichert, Depew, NY). Immobilization of the protein on the hydrophilic carboxymethylated dextran matrix of the sensor chip (Reichert) was carried out using a standard primary amine coupling reaction. Free carboxyl groups on the surface were modified by injecting a mixture of 0.1 M 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and 0.05 M N-hydroxsuccinimide at a flow rate of 20 μL/min to generate a reactive succinimide ester surface. Baseline equilibration was achieved by flushing the chip with PBS buffer for 1–2 h. All of the SPR data was collected at 25°C with PBS as running buffer at a constant flow of 30 μL/min. All the sensorgrams were processed by using automatic correction for nonspecific bulk refractive index effects. All the kinetic analyses of the binding to PPARγ2-LBD were calculated using the Scrubber2 program (Bio-Logic Software).

Statistical analysis. The results are expressed as the means ± standard error of the means (SEM). Data were analyzed using Student’s t-test, with p < 0.05 indicating significance. All experiments were performed in triplicates and were repeated at least three times. Results of representative experiments are shown.

References
1. Yang, S. J., Park, N. Y. & Lim, Y. Anti-adipogenic effect of mulberry leaf ethanol extract in 3T3-L1 adipocytes. Nutr. Res. Pract. 8, 613–617 (2014).
2. Arpil, M. et al. PPARG in Human Adi-pogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms. PPAR Res. 2014, 537865 (2014).
3. Evans, R. M., Barish, G. D. & Wang, Y. X. PPARα and the complex journey to obesity. Nat. Med. 10, 355–361 (2004).
4. Pakala, R. et al. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome. Cardiovasc. Radiat. Med. 5, 97–103 (2004).
5. Takada, I. & Makishima, M. PPARγ ligands and their therapeutic applications: a patent review (2008–2014). Expert Opin. Ther. Pat. 25, 175–191 (2015).
6. Zhang, Y. et al. Protopanaxadiol, a novel PPARgamma antagonist from Panax ginseng, alleviates steatosis in mice. Sci. Rep. 4, 7375 (2014).
7. Rieuxs, I. et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and anti-diabetic activity. Mol. Endocrinol. 16, 2628–2644 (2002).
8. Leesnitzer, L. M. et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640–6650 (2002).
9. Huang, C. et al. Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem. Biophys. Res. Commun. 348, 571–578 (2006).
10. Mangelsdorf, D. J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835–839 (1995).
11. Kojetin, D. J. & Burris, T. P. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol. Pharmacol. 83, 1–8 (2013).
12. Johnson, B. A. et al. Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. J. Mol. Biol. 298, 187–194 (2000).
13. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137–143 (1998).
14. Sheu, S. H., Kaya, T., Waxman, D. J. & Vajda, S. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry 44, 1193–1209 (2005).
15. Kojetin, D. J. & Burris, T. P. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol. Pharmacol. 83, 1–8 (2013).
16. Yang, S. H. et al. SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer. J. Med. Chem. 56, 3414–3418 (2013).
17. Van, H. T. & Cho, W. J. Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolines for the development of novel topoisomerase 1 inhibitors with molecular docking study. Bioorg. Med. Chem. Lett. 19, 2551–2554 (2009).
18. Van, H. T. et al. Synthesis of benzof[3,4]azepto[1,2-b]isoquinolin-9-ones from 3-arylisoquinolines via ring closing metathesis and evaluation of topoisomerase 1 inhibitory activity, cytotoxicity and docking study. Bioorg. Med. Chem. 19, 5311–5320 (2011).
19. Van, H. T. M. et al. Total synthesis of 8-oxypseudopalmitine and 8-oxypseudoberberine via ring-closing metathesis. Tetrahedron 65, 10142–10148 (2009).
20. Jin, Y., Khadka, D. B., Yang, S. H., Zhao, C. & Cho, W. J. Synthesis of novel 5-oxaprotoberberines as bioisosteres of protoberberines. Tetrahedron Lett. 55, 1366–1369 (2014).
21. Jin, Y., Khadka, D. B. & Cho, W. J. Pharmacological effects of berberine and its derivatives: a patent update. Expert Opin. Ther. Pat. 26, 229–243 (2016).
22. Gregoire, F. M., Smas, C. M. & Sul, H. S. Understanding adipocyte differentiation. Physiol. Rev. 78, 783–809 (1998).
23. Aperlo, C., Pognonec, P., Saladin, R., Auwerx, J. & Boulukos, K. E. cDNA cloning and characterization of the transcriptional activities of the hamster peroxisome proliferator-activated receptor haPPAR gamma. Gene 162, 297–302 (1995).
24. Rival, Y. et al. Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. J. Pharmacol. Exp. Ther. 311, 467–475 (2004).
25. Yu, C. et al. Binding analyses between Human PPARgamma-LBD and ligands. Eur. J. Biochem. 271, 386–397 (2004).

Acknowledgements
This work was supported by a grant from the National Research Foundation of Korea (NRF) (Grant 2016R1A2B4009512).

Author Contributions
All authors contributed to the manuscript. Y.J., Y.H., K.Y.L. and W.-J.C. designed research. Y.J. and Y.H. performed most of the work, including synthesis, biological evaluations and data interpretation. D.B.K. and C.Z. participated in synthesis. Y.J. and Y.H. drafted the manuscript, and all authors contributed to the final writing of the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Jin, Y. et al. Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects. Sci. Rep. 6, 34661; doi: 10.1038/srep34661 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/